Abstract: The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.
Abstract: Methods for building peptide chains containing sulfonyl modified amines at the N-terminus, or, within amino acid side chains, of a growing peptide in a solid-phase peptide synthesis are described. Further, compositions having a sulfonyl modified amine attached to the N-terminus, or within an amino acid side chain, of a polypeptide containing three or more amino acid residues are described.
Type:
Grant
Filed:
August 28, 2012
Date of Patent:
November 25, 2014
Assignee:
The University of Toledo
Inventors:
Steven J. Sucheck, Rommel S. Talan, Partha Karmakar
Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antipathogenic, in particular antiviral or/and antibacterial activity. In a preferred aspect, the peptide compounds of the invention have an activity in respect of a broad spectrum of viruses, both DNA and RNA viruses, irrespective of whether they possess virus envelope or not. Further, the present invention refers to compositions comprising said peptidic compounds for medical use, i.e. for the treatment or prevention of pathogenic, in particular viral or/and bacterial infections.
Type:
Grant
Filed:
August 5, 2010
Date of Patent:
November 4, 2014
Assignee:
Spiderbiotech S.r.L.
Inventors:
Andrea Giuliani, Giovanna Pirri, Lorena Pizzuto, Santo Landolfo, Giorgio Gribaudo, David Lembo, Davide Gibellini
Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogous of native hGhrelin.
Type:
Grant
Filed:
August 7, 2008
Date of Patent:
October 28, 2014
Assignee:
Ipsen Pharma S.A.S.
Inventors:
Zheng Xin Dong, Michael DeWitt Culler, Rakesh Datta, John E. Taylor
Abstract: If albumin is added to a pharmaceutical formulation containing acylated insulin described in WO 2009/022005 and WO 2009/022013, the acylated insulin can be kept in solution after subcutaneous injection.
Type:
Grant
Filed:
November 1, 2010
Date of Patent:
October 21, 2014
Assignee:
Novo Nordisk A/S
Inventors:
Helle Naver, Svend Havelund, Peter Madsen
Abstract: A chemoselective chemical ligation method is disclosed. The method joins two peptide segments efficiently to produce a larger peptide or protein, by generating a natural peptide bond (Xaa-Ser and Xaa-Thr) at the ligation site (Xaa represents any 5 amino acid). The method requires two steps (FIG. 1 (a)): a) reacting the starting peptide(s) to form an acetal intermediate with an acetal group at the ligation site; b) converting said acetal intermediate to a desired peptide or protein with said natural peptide bond.
Abstract: The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilised to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the adsorbed immunoglobulin containing proteins; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins. The method improves upon previous separation methods in that each of the ligands comprises one or more of a protein A domain (E, D, A, B, C), or protein Z, or a functional variant thereof, with at least one of the monomers having a substitution of the C-terminal most proline residue after the third alpha-helix.
Abstract: A method of selectively introducing a substituent into a protein proximal to a binding site on the protein for a homing peptide, comprising: (a) contacting the protein with a compound comprising a homing peptide having the ability to bind to the binding site of the protein; and (b) allowing a moiety on the protein proximal to the binding site to react with the compound comprising the homing peptide, thereby to transfer the substituent G onto the protein.
Type:
Grant
Filed:
April 12, 2011
Date of Patent:
October 14, 2014
Assignee:
Novo Nordisk A/S
Inventors:
Mikael Kofod-Hansen, Henning Ralf Stennicke, Soeren Oestergaard, Henrik Oestergaard
Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
Type:
Grant
Filed:
March 11, 2011
Date of Patent:
September 30, 2014
Assignee:
Synageva Biopharma Corp.
Inventors:
Anthony Quinn, Alex J. Harvey, Zhinan Xia
Abstract: The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like.
Type:
Grant
Filed:
August 31, 2012
Date of Patent:
September 30, 2014
Assignee:
Artic Nutrition AS
Inventors:
Hogne Hallaraker, Jan Remmereit, Alvin Berger
Abstract: The present disclosure serves to reduce the healing time of tissue wounds, including those formed during surgery, whether necessary or elective (including cosmetic surgery), by providing a therapeutic dose of a pancreatic enzyme inhibitor.
Type:
Grant
Filed:
September 28, 2010
Date of Patent:
September 23, 2014
Assignee:
The Regents of The University of California
Inventors:
Frank A. DeLano, Geert W. Schmid-Schonbein
Abstract: The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-1 receptor agonistic activity.
Type:
Grant
Filed:
September 28, 2007
Date of Patent:
September 23, 2014
Assignee:
Cadila Healthcare Limited
Inventors:
Rajesh H. Bahekar, Braj Bhushan Lohray, Vidya Bhushan Lohray, Mukul R. Jain, Kaushik M. Banerjee, Pankaj Ramanbhai Patel
Abstract: This invention relates to the coagulation of protein containing nutritional compositions in the upper gastro-intestinal tract, more in particular in the stomach and provides a method for reducing suchcoagulation.
Type:
Grant
Filed:
April 27, 2010
Date of Patent:
September 16, 2014
Assignee:
N.V. Nutricia
Inventors:
Thomas Ludwig, Claudia Catharina Maria van den Braak, Marianne Klebach, Zandrie Hofman
Abstract: The present invention relates to processes for extracting lipid from vegetative plant parts such as leaves, stems, roots and tubers, and for producing industrial products such as hydrocarbon products from the lipids. Preferred industrial products include alkyl esters which may be blended with petroleum based fuels.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
August 19, 2014
Assignee:
Commonwealth Scientific and Industrial Research Organisation
Inventors:
Thomas Vanhercke, James Robertson Petrie, Anna El Tahchy, Surinder Pal Singh, Qing Liu
Abstract: The invention relates to optimized adhesins and nanoparticles to which said adhesins are bound. The invention furthermore relates to providing said nanoparticles by way of in vivo contrast agents, in particular for the diagnosis of bowel cancer.
Type:
Grant
Filed:
June 17, 2008
Date of Patent:
August 5, 2014
Assignee:
Signalomics GmbH
Inventors:
Christoph Block, Karin Mittmann, Claudia Arntz
Abstract: Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
Type:
Grant
Filed:
June 14, 2011
Date of Patent:
July 15, 2014
Assignee:
Indiana University Research and Technology Corporation
Abstract: The present invention relates to the use of fragments of heat shock proteins for the treatment and/or prevention of autoimmune diseases such as arthritis or inflammatory diseases such as Inflammatory Bowel Diseases. Preferably bacterial and/or mammalian heat shock proteins belonging to the HSP70 families are used.
Abstract: The present invention relates to processes for producing industrial products such as hydrocarbon products from non-polar lipids in a vegetative plant part. Preferred industrial products include alkyl esters which may be blended with petroleum based fuels.
Type:
Grant
Filed:
December 21, 2012
Date of Patent:
May 27, 2014
Assignee:
Commonwealth Scientific and Industrial Research Organisation
Inventors:
Thomas Vanhercke, James Robertson Petrie, Anna El Tahchy, Surinder Pal Singh, Qing Liu
Abstract: Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
Type:
Grant
Filed:
June 14, 2011
Date of Patent:
May 20, 2014
Assignee:
Indiana University Research and Technology Corporation